Teva concludes nationwide opioids settlement up to $4.25B; resolves all 50 states and >99% subdivisions

TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva will pay up to $4.25B over 13 years, including $1.2B of generic Narcan (or $240M cash) to participating states and subdivisions.
Separate settlement with Nevada for $193M over 20 years, averting trial scheduled for August 2023.
Settlement becomes effective August 7, 2023; first payments expected in H2 2023, with Narcan shipments already begun.
Teva has now resolved opioid claims with all 50 U.S. states and more than 99% of litigating subdivisions and special districts.
Agreement includes no admission of wrongdoing; company avoids further litigation uncertainty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.